Antigen-binding molecules that repeatedly bind to multiple antigen molecules.
JP2026094161APending Publication Date: 2026-06-09CHUGAI PHARMA CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- CHUGAI PHARMA CO LTD
- Filing Date
- 2026-02-05
- Publication Date
- 2026-06-09
AI Technical Summary
Benefits of technology
【0014】 本発明によって、抗原結合分子による抗原の細胞内への取込みを促進させる方法、1分子の抗原結合分子により抗原への結合回数を増加させる方法、抗原結合分子の投与により血漿中の抗原濃度の減少を促進させる方法、抗原結合分子の血漿中滞留性を改善する方法が提供された。抗原結合分子による抗原の細胞内への取込みが促進されることで、抗原結合分子の投与により抗原の血漿中の抗原濃度の減少を促進させることが可能となるとともに、抗原結合分子の血漿中滞留性を改善させることが可能となり、1分子の抗原結合分子により抗原への結合回数を増加させることが可能となり、in vivoにおいて通常の抗原結合分子よりも優れた効果を発揮させることができる。
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026094161000057 
Figure 2026094161000058 
Figure 2026094161000059
Abstract
The present invention provides antigen-binding molecules that promote the uptake of antigens into cells, antigen-binding molecules with an increased number of antigen binding cycles, antigen-binding molecules that can promote a decrease in plasma antigen concentration upon administration, and antigen-binding molecules with improved plasma retention. [Solution] An antigen-binding molecule comprising an antigen-binding domain and a human FcRn-binding domain, wherein the antigen-binding activity differs under two different calcium concentration conditions, the antigen-binding activity under low calcium concentration conditions is lower than the antigen-binding activity under high calcium concentration conditions, and the antigen-binding molecule has binding activity to human FcRn under neutral pH conditions.
Need to check novelty before this filing date? Find Prior Art
Claims
[Claim 1] The invention described herein.